C. Wadsworth

发表

Durvalumab after Chemoradiotherapy in Stage III Non–Small‐Cell Lung Cancer

Tarek Mekhail, Maike de Wit, Kaoru Kubota, 2017, The New England journal of medicine.

Durvalumab as third-line or later treatment for advanced non-small-cell lung cancer (ATLANTIC): an open-label, single-arm, phase 2 study.

Keunchil Park, N. Rizvi, J. Mazières, 2018, The Lancet. Oncology.

Three-Year Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC—Update from PACIFIC

D. Planchard, C. Faivre-Finn, L. Paz-Ares, 2019, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Outcomes with durvalumab by tumour PD-L1 expression in unresectable, Stage III non-small-cell lung cancer in the PACIFIC trial.

D. Planchard, C. Faivre-Finn, S. Senan, 2020, Annals of oncology : official journal of the European Society for Medical Oncology.

Three-year overall survival update from the PACIFIC trial.

D. Planchard, C. Faivre-Finn, L. Paz-Ares, 2019, Journal of Clinical Oncology.

Final overall survival and safety update for durvalumab in third- or later-line advanced NSCLC: The phase II ATLANTIC study.

Keunchil Park, N. Rizvi, J. Mazières, 2020, Lung cancer.

Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC

D. Planchard, C. Faivre-Finn, L. Paz-Ares, 2018, The New England journal of medicine.

MA05.02 PACIFIC Subgroup Analysis: Pneumonitis in Stage III, Unresectable NSCLC Patients Treated with Durvalumab vs. Placebo After CRT

C. Faivre-Finn, J. Vansteenkiste, P. Dennis, 2018, Journal of Thoracic Oncology.

PL04a.03: Durvalumab in ≥3rd-Line Locally Advanced or Metastatic, EGFR/ALK Wild-Type NSCLC: Results from the Phase 2 ATLANTIC Study

N. Rizvi, J. Mazières, J. Vansteenkiste, 2017 .

Impact of Patient Characteristics, Prior Therapy, and Sample Type on Tumor Cell Programmed Cell Death Ligand 1 Expression in Patients with Advanced NSCLC Screened for the ATLANTIC Study.

N. Rizvi, P. Dennis, M. Garassino, 2019, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Impact of prior chemoradiotherapy-related variables on outcomes with durvalumab in unresectable Stage III NSCLC (PACIFIC).

C. Faivre-Finn, S. Senan, L. Paz-Ares, 2020, Lung cancer.

Efficacy of durvalumab in patients with stage III NSCLC who experience pneumonitis (PACIFIC)

C. Faivre-Finn, J. Vansteenkiste, P. Dennis, 2019, Annals of Oncology.

Three-year overall survival update from the PACIFIC trial

D. Planchard, C. Faivre-Finn, L. Paz-Ares, 2019, Annals of Oncology.

82ODurvalumab in ≥ 3rd-line EGFR mutant/ALK+, locally advanced or metastatic NSCLC: Results from the phase 2 ATLANTIC study

N. Rizvi, J. Mazières, P. Dennis, 2017 .

Efficacy and safety evaluation based on time from completion of radiotherapy to randomization with durvalumab or placebo in pts from PACIFIC.

C. Faivre-Finn, S. Senan, D. Raben, 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

Symptomatic Pneumonitis With Durvalumab After Concurrent Chemoradiotherapy in Unresectable Stage III NSCLC

J. Naidoo, A. Villegas, C. Wadsworth, 2024, JTO clinical and research reports.